OBJECTIVE: To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment. MATERIALS AND METHODS: Two target tumors were prospectively analyzed in 12 patients at baseline, 2-weeks and 2-months treatment using b values of 0, 200, 400, 800 s/mm. Repeatability error was estimated on a healthy volunteer. RESULTS: Lesion sizes, ADC and D values did not significantly change during treatment (overall mean values, respectively, 47.8 ± 31.0 mm, 1.34 ± 0.14 × 10⁻³ mm² s and 1.18 ± 0.22 × 10⁻³ mm²/s). However, f values significantly increased in seven responder patients (+38.39% at 2-weeks, +50.94% at 2-months, P = 0.005) while they decreased in five non responder patients (-41.93% at 2-weeks, P = 0.006). Furthermore, f was inversely correlated with αFP levels (P = 0.032) and responder patients had a higher mean overall survival (OS) than non responder patients (12.29 ± 4.46 vs. 7.80 ± 4.9 months). The % variation of f relative to baseline at 2-months was correlated with OS (P = 0.038) and symptomatic time to progression (P = 0.022). CONCLUSION: Contrary to ADC and D, the perfusion fraction f is a valuable marker of sorafenib treatment in advanced HCC.
OBJECTIVE: To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment. MATERIALS AND METHODS: Two target tumors were prospectively analyzed in 12 patients at baseline, 2-weeks and 2-months treatment using b values of 0, 200, 400, 800 s/mm. Repeatability error was estimated on a healthy volunteer. RESULTS: Lesion sizes, ADC and D values did not significantly change during treatment (overall mean values, respectively, 47.8 ± 31.0 mm, 1.34 ± 0.14 × 10⁻³ mm² s and 1.18 ± 0.22 × 10⁻³ mm²/s). However, f values significantly increased in seven responder patients (+38.39% at 2-weeks, +50.94% at 2-months, P = 0.005) while they decreased in five non responder patients (-41.93% at 2-weeks, P = 0.006). Furthermore, f was inversely correlated with αFP levels (P = 0.032) and responder patients had a higher mean overall survival (OS) than non responder patients (12.29 ± 4.46 vs. 7.80 ± 4.9 months). The % variation of f relative to baseline at 2-months was correlated with OS (P = 0.038) and symptomatic time to progression (P = 0.022). CONCLUSION: Contrary to ADC and D, the perfusion fraction f is a valuable marker of sorafenib treatment in advanced HCC.
Authors: Ihab R Kamel; Eleni Liapi; Diane K Reyes; Marianna Zahurak; David A Bluemke; Jean-François H Geschwind Journal: Radiology Date: 2009-02 Impact factor: 11.105
Authors: Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen Journal: Nat Rev Clin Oncol Date: 2009-06 Impact factor: 66.675
Authors: Tejas Parikh; Stephen J Drew; Vivian S Lee; Samson Wong; Elizabeth M Hecht; James S Babb; Bachir Taouli Journal: Radiology Date: 2008-01-25 Impact factor: 11.105
Authors: Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Z Xiao; Z Tang; J Qiang; S Wang; W Qian; Y Zhong; R Wang; J Wang; L Wu; W Tang; Z Zhang Journal: AJNR Am J Neuroradiol Date: 2018-01-25 Impact factor: 3.825
Authors: P Mürtz; A M Sprinkart; M Reick; C C Pieper; A-H Schievelkamp; R König; H H Schild; W A Willinek; G M Kukuk Journal: Eur Radiol Date: 2018-04-18 Impact factor: 5.315